Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Atezolizumab

Patients with Non-Small Cell Lung Cancer Treated with Atezolizumab

1. .Analysis of immune marker using FACS before treatment and Cycle1, Cycle2, Cycle3 and the time of disease progression.
2. .Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) at pre-treatment and progression (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)

3. microbiome Pretreatment stool sample will be collected. (Stool sample is optional)

4.Genetic analysis For RNAseq or exome seq, biopsied tissue at baseline or progression are optional.

4.Single cell RNA sequencing (scRNA-seq) scRNA-seq will be performed by collecting selectively tissues from pre-treatment tumor biopsies and at relapse/acquired resistance tumor biopsies. Screening and treatment biopsies are optional.

Sample collection

Hye Ryun Kim, Ph.D

The study aimed to elucidate predictive immune related biomarker to the responsiveness to the PD-L1 blockade and evaluate the dynamics of immune cells in peripheral blood from NSCLC patients during atezolizumab treatment.

A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Multiplexed biomarker analysis of tumor and immune cells in tumor microenvironment (TME) (Pre-treatment biopsy is mandatory but biopsy is optional for disease progression)

The manner and interval of efficacy assessment for tumor scan will depends on the investigator's decision.

Overall survival will be followed continuously while subjects are on the study drug and every 6 months after discontinuation or progression for up to 5 years following the start of therapy either by direct contact (office visits) or via telephone contact, until death, withdrawal of study consent, or lost to follow-up. Overall survival is defined as the time between the start of treatment and the date of death due to any cause.

Number of participants with adverse events and abnormal laboratory values as assessed by NCI-CTCAE version 5

Spots Global Cancer Trial Database for A Study for Identification of Predictive Immune Biomarker for Atezolizumab Therapy in NSCLC Patients

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial